Clinical Trial Update: Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated glutamine as a myocardial protector in elective on-pump CABG surgery for patients with low ejection fraction; the study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Bypass Grafting Complication
• Coronary Artery Disease
• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Glutamine (glutamine)

Snippet

Sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia | Conditions: Coronary Artery Bypass, Cardiopulmonary Bypass | Phase 3 | Status: COMPLETED | Results posted: 2023-11-13